Daniel Faga Sells 3,000 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) Stock

AnaptysBio, Inc. (NASDAQ:ANAB) CEO Daniel Faga sold 3,000 shares of the company’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $21.42, for a total transaction of $64,260.00. Following the completion of the transaction, the chief executive officer now owns 749,087 shares of the company’s stock, valued at approximately $16,045,443.54. The sale was disclosed in a filing with the SEC, which is available at this link.

Daniel Faga also recently made the following trade(s):

• On Friday, March 22nd, Daniel Faga sold 145,940 shares of AnaptysBio stock. The shares were sold at an average price of $22.78, for a total transaction of $3,324,513.20.
• On Monday, January 8th, Daniel Faga sold 6,866 shares of AnaptysBio stock. The shares were sold at an average price of $21.81, for a total transaction of $149,747.46.

AnaptysBio Stock Performance

Shares of AnaptysBio stock opened at $21.38 on Thursday. The company has a market cap of $572.13 million, a P/E ratio of -3.52 and a beta of -0.28. AnaptysBio, Inc. has a one year low of $13.36 and a one year high of $27.50. The firm has a fifty day moving average of $24.00 and a two-hundred day moving average of $20.21.

Wall Street Analyst Weigh In

ANAB has been the subject of several research reports. Wedbush upgraded shares of AnaptysBio from a “neutral” rating to an “outperform” rating and upped their price target for the company from $20.00 to $34.00 in a research report on Tuesday, March 12th. Stifel Nicolaus initiated coverage on shares of AnaptysBio in a research report on Wednesday, February 21st. They issued a “buy” rating and a $50.00 price target for the company. BTIG Research initiated coverage on shares of AnaptysBio in a research report on Monday, February 26th. They issued a “buy” rating and a $55.00 price target for the company. Finally, Piper Sandler assumed coverage on shares of AnaptysBio in a research report on Friday, February 16th. They issued an “overweight” rating and a $80.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. According to MarketBeat, AnaptysBio currently has an average rating of “Moderate Buy” and a consensus target price of $45.00.

Hedge Funds Weigh In On AnaptysBio

A number of large investors have recently bought and sold shares of ANAB. Quantbot Technologies LP purchased a new position in shares of AnaptysBio in the 2nd quarter valued at about $34,000. Tower Research Capital LLC TRC increased its holdings in shares of AnaptysBio by 248.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,596 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 2,565 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of AnaptysBio by 350.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 2,390 shares in the last quarter. BNP Paribas Arbitrage SA increased its holdings in shares of AnaptysBio by 75.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,984 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 2,142 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of AnaptysBio by 134.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company’s stock valued at $106,000 after purchasing an additional 3,381 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.